Biotechnology Industry · global
CSL commits $355 million to partnership with Alentis to advance antibody therapy for rare kidney and liver diseases
An antibody targeting inflammation and fibrosis has secured backing from a major pharmaceutical company and will move toward larger clinical trials. The partnership funding paves the way for development, but early signs of improved organ function remain some distance from proving that the treatment can prevent disease progression.
After the immune system attacks the kidneys, organ damage may continue even when inflammation is brought under control. Preserving kidney function is a challenge in treating rare kidney diseases. Australian biotechnology company CSL announced on October 5 that it had established an exclusive global partnership with Switzerland’s Alentis Therapeutics to jointly develop and market the investigational antibody lixudebart and cover development costs for multiple trials in kidney and liver diseases.
According to CSL’s announcement, Alentis will receive an upfront payment of $355 million, plus up to $1.2 billion in commercial milestone payments. Once the product is commercialized, CSL will receive 55% of global profits and Alentis 45%. Dow Jones Newswires also confirmed these terms. Reuters summarized the potential deal value as approximately $1.6 billion, but that includes payments contingent on conditions being met and excludes additional development funding.
The scientific core of this partnership is a treatment concept that addresses inflammation and fibrosis simultaneously. Lixudebart is a monoclonal antibody targeting claudin-1 exposed on the cell surface. According to the company, this protein is involved in inflammatory and fibrotic signaling in damaged tissue. The development team hopes to reduce organ damage through this approach, but preventing or even reversing damage remains a goal that requires clinical validation.
The initial development priority is ANCA-associated vasculitis with rapidly progressive glomerulonephritis, abbreviated as AAV-RPGN. This type of autoimmune disease attacks small blood vessels in the kidneys and can cause a severe decline in kidney function within a short period. CSL will fully fund the ongoing Phase 2 RENAL trial, a planned Phase 3 trial, and Phase 2 trials in focal segmental glomerulosclerosis and primary sclerosing cholangitis, allowing the same antibody to be tested across different diseases.
The early data supporting the partnership still come primarily from company disclosures. CSL said an interim analysis of 26 patients in the RENAL trial showed signs of improved kidney function at 24 weeks, assessed using estimated glomerular filtration rate and proteinuria. Another study, the Phase 1b FEGATO trial, observed what the company described as improved liver function at six weeks in 41 patients with advanced liver fibrosis. Both studies were also described as having favorable safety and tolerability.
These results provide a rationale for further trials, but are not yet sufficient to establish therapeutic benefit. The partnership announcement did not provide full between-group differences, statistical analyses, or the distribution of adverse events. Results in patients with advanced liver fibrosis also cannot be treated directly as evidence of efficacy in primary sclerosing cholangitis. Whether short-term changes in organ function measures can translate into lasting protection and a reduced risk of end-stage kidney disease remains a question for more comprehensive and longer-term studies.
For CSL, the deal is also part of its strategy to expand its kidney disease business. Reuters cited analyst Kyle Rodda as saying that the partnership offers potential for profit growth, but the deal alone may not be enough to significantly improve the company’s long-term growth outlook. Funding and global development capabilities are now in place. What determines this antibody’s value next will be whether it can deliver reproducible results with meaningful benefits for patients in trials across different diseases.